Verve Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Rhea-AI Summary

Verve Therapeutics (VERV), a clinical-stage biotechnology company focused on developing genetic medicines for cardiovascular disease, has announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference. Dr. Sekar Kathiresan, the company's co-founder and CEO, will deliver a presentation on Wednesday, January 15, 2025, at 11:15 a.m. PT in San Francisco.

The presentation will be accessible through a live webcast on the investor section of Verve's website at www.vervetx.com. Interested parties can access the archived version of the webcast for 30 days following the presentation.

News Market Reaction – VERV

-6.39%

-6.39% Session move

In the trading session that priced this news, VERV declined 6.39%, reflecting a notable negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

BOSTON, Jan. 08, 2025 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage company developing a new class of genetic medicines for cardiovascular disease, today announced that Sekar Kathiresan, M.D., co-founder and chief executive officer, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2025 at 11:15 a.m. PT in San Francisco.

A live webcast will be available in the investor section of the company’s website at www.vervetx.com. The webcast will be archived for 30 days following the presentation.

About Verve Therapeutics 
Verve Therapeutics, Inc. (Nasdaq: VERV) is a clinical-stage company developing a new class of genetic medicines for cardiovascular disease with the potential to transform treatment from chronic management to single-course gene editing medicines. The company’s lead programs – VERVE-101, VERVE-102, and VERVE-201 – target genes that have been extensively validated as targets for lowering low-density lipoprotein cholesterol (LDL-C), a root cause of atherosclerotic cardiovascular disease (ASCVD). VERVE-101 and VERVE-102 are designed to permanently turn off the PCSK9 gene in the liver and are being developed initially for heterozygous familial hypercholesterolemia (HeFH) and ultimately to treat patients with established ASCVD who continue to be impacted by high LDL-C levels. VERVE-201 is designed to permanently turn off the ANGPTL3 gene in the liver and is initially being developed for refractory hypercholesterolemia, where patients still have high LDL-C despite treatment with maximally tolerated standard of care therapies, and homozygous familial hypercholesterolemia (HoFH). For more information, please visit www.VerveTx.com.

Investor Contact
Jen Robinson
Verve Therapeutics, Inc.
jrobinson@vervetx.com

Media Contact
Ashlea Kosikowski
1AB
ashlea@1abmedia.com

FAQ

When is Verve Therapeutics (VERV) presenting at the 2025 J.P. Morgan Healthcare Conference?

Verve Therapeutics will present on Wednesday, January 15, 2025, at 11:15 a.m. PT in San Francisco.

How can investors access VERV's J.P. Morgan Healthcare Conference presentation?

Investors can access the presentation through a live webcast available in the investor section of Verve's website at www.vervetx.com.

How long will VERV's J.P. Morgan Conference presentation be available for replay?

The webcast will be archived and available for 30 days following the presentation.

What type of medicines is Verve Therapeutics (VERV) developing?

Verve Therapeutics is developing a new class of genetic medicines focused on treating cardiovascular disease.

Who will be presenting for Verve Therapeutics (VERV) at the J.P. Morgan Healthcare Conference?

Dr. Sekar Kathiresan, co-founder and chief executive officer of Verve Therapeutics, will be presenting at the conference.